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Abstract
Bone metastases are a common clinical problem, affecting many types of cancer patients. The presence of
tumor in bone can cause significant morbidity including pain, neurological dysfunction, hypercalcemia, and
pathological fracture leading to functional loss. The optimal treatment of a patient with bone metastases
depends on many factors, including evaluation of the patient’s goals of care, performance status, mechanical
stability of the affected bone, life expectancy, and overall extent of disease. Treatment options may include
radiotherapy, systemic therapies, surgical stabilization, medical pain management, and radiopharmaceuticals.
Ideal management of bone metastases requires a coordinated multidisciplinary approach among diagnostic
radiologists, radiation oncologists, medical oncologists, orthopedic surgeons, pain specialists, physiatrists, and
palliative care specialists. The American College of Radiology Appropriateness Criteria are evidence-based
guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel.
The guidelines development and review include an extensive analysis of current medical literature from peer-
reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate
the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is
lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Introduction
Bone is a common site of metastasis, affecting patientswith a wide variety of malignancies including breast,
prostate, lung, colorectal, bladder, endometrial, thyroid,
kidney, myeloma, and melanoma. The presence of tumor in
bone can cause significant morbidity including pain, neuro-
logical dysfunction, hypercalcemia, and pathological fracture
leading to significant functional loss. The optimal treatment
of a patient with bone metastases depends on many factors,
including evaluation of the patient’s goals of care, perfor-
mance status, mechanical stability of the affected bone, life
expectancy, and overall extent of disease. Both osteolytic and
osteoblastic lesions may be associated with pain and risk
of fracture. Management decisions frequently involve col-
laboration among several types of specialists, including
diagnostic radiologists, radiation oncologists, medical on-
cologists, surgeons, pain medicine specialists, physiatrists,
and palliative care professionals. Similar to the approaches
used for patients treated with curative intent, optimal man-
agement of patients with bone metastases requires multidis-
ciplinary consideration of localized therapies such as surgery
and external beam radiation therapy (EBRT) with systemic
therapies including pain medications, chemotherapy, hor-
monal therapy (HT), osteoclast inhibitors (OI), and radio-
pharmaceuticals.1–5
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Oftentimes, patients who present with multifocal bone
metastases are treated first with medical therapies including
narcotics, chemotherapy, HT, bisphosphonates, radiophar-
maceuticals, and RANK ligand inhibitors. EBRT is usually
reserved for when a specific metastatic lesion causes signif-
icant local symptoms such as pain or creates a risk for
pathological fracture or neurological injury. Surgical stabi-
lization can treat or prevent the morbidity of a pathological
fracture, particularly in weight-bearing bones. In addition,
the alpha-emitting radiopharmaceutical therapy, radium 223
dichloride, has a place in the management of patients with
castration-resistant prostate cancer, symptomatic bone me-
tastases, and no known visceral metastatic disease.6,7
Variant 1 Discussion
This patient has newly diagnosed metastatic disease at a
single site (femur), an excellent performance status, and has
not previously received systemic therapy. Systemic therapy
(including biologic agents, chemotherapy, and OI) will be
critical for systemic disease control. However, he is at ele-
vated risk of developing pathological fracture in the near
future and would benefit from immediate attention to the
femoral lesion.
The most useful means of predicting the risk for patho-
logical fracture includes evaluation by a published scoring
system based on anatomical site, degree of pain, type of le-
sion (blastic, mixed, lytic), and tumor size.8 Another sim-
plified method of predicting pathological fracture in the
femur describes an elevated risk in lesions with > 3 cm cor-
tical involvement.9
This patient should be evaluated by an orthopedic surgeon
for consideration of surgical stabilization of the femur. If he
undergoes surgical stabilization, postoperative radiotherapy
should be considered. If he does not undergo surgical stabi-
lization, then immediate radiotherapy is indicated. The goals
of therapy would be to control pain as well as preserve am-
bulatory function.
Radiation can be delivered to this site most efficiently
through parallel opposed anterior and posterior fields. A strip
of skin and soft tissue, as large as possible, should be spared
to reduce the risk of long-term lower-extremity lymphedema,
which can be associated with full-circumference extremity
radiation.
This patient also has oligometastatic disease. The optimal
management of oligometastases is an active area of research.
Investigations comparing site-specific localized therapy with
a more systemic approach with or without localized therapy
are ongoing. Some have argued that patients with minimal
sites of bone-only metastatic disease (deemed ‘‘oligometa-
static’’) from certain disease may be treated with curative
intent, although the data to confirm that stance are still to be
accrued.10
Single-fraction radiotherapy (8 Gy · 1), when compared
with higher-dose multifraction regimens, has been associ-
ated with a higher risk of postradiation pathological fracture
in femoral metastases. If this patient does not undergo sur-
gical stabilization, then a higher-dose multifraction regimen
would be reasonable.9 Local therapy should be followed
by systemic therapy including consideration of OI. In light
of the slight risk of jaw osteonecrosis associated with OI
administration, a pretreatment dental evaluation to assess
dentition and potential risk prior to OI use might be war-
ranted (Table 1).
Variant 2 Discussion
This patient has a good performance status and multiple
sites of metastatic disease, but has a symptomatic lesion in a
non–weight-bearing bone. This patient has a life expectancy
that may be measured in years. This patient (as all patients)
should receive appropriate analgesic therapy as a first-line
treatment to provide rapid relief.
In general, the setup and prescription points for treatment
should follow those outlined by the international consensus
on palliative radiotherapy endpoints for future clinical trials,
which were updated recently.11 Fluoroscopic simulation,
computed tomography (CT) simulation, and clinical simu-
lation are all acceptable methods for planning radiation fields.
There are no data to suggest that highly conformal therapy
with intensity-modulated radiation therapy (IMRT), stereo-
tactic body radiation therapy (SBRT), proton therapy, or
brachytherapy would improve the outcome for this patient.
EBRT provides at least partial pain relief in 50% to 80% of
patients, and most series suggest a rate of complete pain relief
in about one-third of patients.12 Although a recent interna-
tional survey showed 101 different dose schedules in com-
mon use for treating painful bone metastases with EBRT, the
rates of pain relief are equivalent for fractionation schemes
including 30 Gy in 10 fractions, 24 Gy in 6 fractions, 20 Gy in
5 fractions, and a single 8 Gy fraction.2,13 Single-fraction
treatment optimizes patient convenience and reduces acute
side effects but is associated with an approximate 20% rate of
retreatment to the same site compared with an 8% retreatment
rate with the more prolonged courses.12–14
Due to the presence of multifocal disease, systemic therapy
options should be explored, and current practice patterns also
should include consideration of the use of OI. If both palli-
ative radiotherapy and palliative systemic chemotherapy are
to be delivered to this patient, they should be given sequen-
tially rather than concurrently. OI have the ability to decrease
the risk of skeletal-related events (fracture, need for surgery
or radiation to bone, spinal cord compression, and hyper-
calcemia of malignancy) as well as the ability to decrease
pain from bone metastases and improve quality of life in
patients with certain disease histologies.15 OI therapy is an
adjunctive therapy to radiation. In addition, it may alleviate
metastatic bone pain, and it is routinely administered indef-
initely.16 Inhibiting osteoclast activity does not appear to
impart a survival advantage. Recognized effects of the toxi-
cities of potent OI include renal dysfunction (with intrave-
nous bisphosphonates), hypocalcemia, and osteonecrosis of
the jaw (Table 2).
Variant 3 Discussion
This patient has pain at a site that has been previously
irradiated. She had initial pain relief with treatment. Avail-
able data frommultiple smaller, retrospective studies suggest
that retreatment with EBRTmay provide a reasonable chance
of pain relief in 33% to 84% of patients.17,18 A recent meta-
analysis of 10 studies, including data from 2694 patients,
estimated pain response in 58% of patients who received
reirradiation for painful bone metastases.19 A recently com-
pleted international randomized prospective Phase III trial
12 KIM ET AL.
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compared a single-fraction (8 Gy x 1) reirradiation schedule
with a multiple-fraction regimen (20 Gy in 5 to 8 fractions) in
850 patients with previously irradiated bone metastases. The
majority of patients had prostate, breast, or lung cancer. The
single-fraction regimen was not inferior to the multiple-
fraction regimen with respect to pain control assessment
at 2 months. Acute toxicities were worse in the multiple-
fraction arm.20,21
As in any case of reirradiation, care should be taken to
avoid combined doses greater than the normal tissue toler-
ances of structures within the retreated volumes. The recur-
rence of pain in any long bone necessitates a reassessment of
pathological fracture risk before delivering reirradiation.
Treatment should be planned to spare a skin and soft-tissue
strip to minimize the risk of developing late chronic upper
extremity lymphedema. Fluoroscopic simulation, CT simu-
lation, and clinical simulation are all acceptable methods for
planning radiation fields. There are no data to suggest that
highly conformal therapy with IMRT, SBRT, brachytherapy,
or proton therapy would improve the outcome for this patient.
Systemic chemotherapy can be considered depending on
the patient’s previous exposure to chemotherapy and her
tolerance of further therapy. This patient’s disease has pro-
gressed on bisphosphonates, and RANK ligand inhibitors
may be of use. If cytotoxic therapy is considered, it should be
delivered sequentially with palliative radiotherapy rather
than concurrently. Duration of radiation therapy should be
weighed against the urgency of initiating a new line of sys-
temic therapy. A shorter course of palliative reirradiation
would potentially delay chemotherapy less than a longer
treatment course.
The American Society of Clinical Oncology guidelines for
the use of bone modifying agents in metastatic breast cancer
recommend the use of OI, bisphosphonate or denosumab, be
continued until there is evidence of substantial decline in the
patient’s clinical status.16 These drugs may reduce the risk of
Table 1. Clinical Condition: Non-Spine Bone Metastases, Variant 1
52-year-oldman with a history of a T1N0M0 non–small-cell lung cancer. Two years after lobectomy, he is found to have a painful
metastasis in the right femoral neck. The lesion is 3.5 cm in size with > 50% erosion of the medial bone cortex. Karnofsky
Performance Status (KPS) 90. No other metastatic disease is found. He has had no previous therapy other than lobectomy.
Treatment Rating Comments
Surgical intervention followed by EBRT, then systemic
therapy
9
Surgical intervention followed by systemic therapy alone 5
EBRT alone 3 This treatment is associated with a high risk of
pathological fracture without prophylactic internal
fixation, as evaluated by certain criteria.8
EBRT followed by systemic therapy 3 This treatment is associated with a high risk of
pathological fracture without prophylactic internal
fixation, as evaluated by certain criteria.8
Surgical intervention alone 3
Hospice after treatment of the femur 2
Systemic therapy alone (may include biologic agents,
bisphosphonates, and/or chemotherapy)
2
Observation 1
Direct hospice placement 1
Radiation therapy dose
8 Gy/1 fraction 4
20 Gy/5 fractions 5
24 Gy/6 fractions 6 A high biologically effective dose of radiation may be
beneficial for this patient with an excellent KPS and
oligometastatic disease.
30 Gy/10 fractions 8
35 Gy/14 fractions 4
40 Gy/20 fractions 4
Treatment technique
Clinical simulation 5
Fluoroscopic simulation or 2-D RT 7
CT simulation 8
AP/PA 8
3-D CRT 8
IMRT 3
SBRT 2
Proton therapy to the bone metastasis 2
Rating Scale: 1,2,3 usually not appropriate; 4,5,6 may be appropriate; 7,8,9 usually appropriate.
AP/PA, anteroposterior/posteroanterior; CRT, conformal radiation therapy; CT, computed tomography; EBRT, external beam radiation
therapy; IMRT, intensity-modulated radiation therapy; SBRT, stereotactic body radiation therapy.
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subsequent skeletal-related events and may aid in controlling
bone pain. It is of note that in the pooled analysis of the Phase
III studies of denosumab versus zoledronic acid, denosumab
demonstrated superiority in delaying the time to subsequent
skeletal-related events with a relative risk of 0.82 (95%
confidence interval [CI], 0.75 to 0.90), p < 0.001 (Table 3).22
Variant 4 Discussion
This patient has been heavily pretreated for metastatic
prostate cancer and now has hormone-refractory disease. The
patient may consider additional systemic therapy. As his bone
metastases appear relatively symptomatic, sipuleucel-T is not
a likely next step. Abiraterone/prednisone and enzalutamide
may be considered options if not used already.23–25 Note
that enzalutamide is FDA approved for disease progression
after docetaxel therapy. In addition, a clinical trial, cabo-
zantinib, or mitoxantrone may be options for this individual
depending on his goals of care, marrow reserve, and per-
formance status.25,26
Although it may be technically possible to deliver EBRT to
multiple symptomatic lesions, the patient’s burden of disease
suggests he may be a favorable candidate for radiophar-
maceutical therapy. Multiple series have reported pain re-
sponse rates ranging from 45% to 80%with samarium-153 or
strontium-89.27–29 An international prospective randomized
trial of radium-223 versus placebo showed improvements in
quality of life scores, decreased skeletal events, and im-
proved overall survival with administration of radium-223.7
Table 2. Clinical Condition:
Non-Spine Bone Metastases, Variant 2
62-year-old woman with estrogen-receptor positive/proges-
terone-receptor positive breast cancer, Her-2/neu non-
amplified. She develops a painful lytic bone metastasis in the
right humerus after 4 years of a single line of adjuvant hor-
monal therapy. There is minimal invasion of bone cortex, and
the lesion is thought to have a low fracture risk per ortho-
pedic surgery consult. Karnofsky Performance Status (KPS)
is 90. Bone scan demonstrates a few other asymptomatic
bone metastases.
Treatment Rating Comments
EBRT followed by systemic therapy 8
Systemic therapy alone
(hormonal therapy and
bisphosphonates
or RANK ligand inhibitor)
4
EBRT alone 3
Radiopharmaceuticals 2
Surgical intervention 2
Direct hospice placement 1
Hospice after treatment
of the humerus
1
Radiation therapy dose
8 Gy/1 fraction 8
20 Gy/5 fractions 8
24 Gy/6 fractions 8
30 Gy/10 fractions 8
35 Gy/14 fractions 5
40 Gy/20 fractions 3
Treatment technique
Clinical simulation 5
Fluoroscopic simulation
or 2-D RT
7
CT simulation 8
AP/PA 8
3-D CRT 8
IMRT 2
SBRT 2
Proton therapy to the
bone metastasis
2
Rating Scale: 1,2,3 usually not appropriate; 4,5,6 may be
appropriate; 7,8,9 usually appropriate.
AP/PA, anteroposterior/posteroanterior; CRT, conformal radiation
therapy; CT, computed tomography; EBRT, external beam radiation
therapy; IMRT, intensity-modulated radiation therapy; SBRT,
stereotactic body radiation therapy.
Table 3. Clinical Condition:
Non-Spine Bone Metastases, Variant 3
65-year-old woman with metastatic hormone-receptor posi-
tive breast cancer currently on hormonal and bisphosphonate
therapy for skeletal-dominant metastatic disease. She re-
ceived palliative radiation (30 Gy/10 fractions) to a painful
lesion in the right humerus 3 years ago with good pain relief
but now has recurrent pain at this site. Radiographs show a
lytic lesion with no radiographic evidence of impending
fracture. She has several other asymptomatic skeletal lesions
and a new 1.5-cm lung metastasis.
Treatment Rating Comments
EBRT reirradiation to
symptomatic lesion
8
Consider changes to
systemic therapy only
5
Radiopharmaceuticals 3
Surgical intervention 3
Direct hospice placement 2
Hospice after treatment
of the humerus
2
Radiation therapy dose
8 Gy/1 fraction 8
20 Gy/5 fractions 8
24 Gy/6 fractions 8
30 Gy/10 fractions 7
35 Gy/14 fractions 5
40 Gy/20 fractions 3
Treatment technique
Clinical simulation 5
3-D CRT 8
Fluoroscopic simulation
or 2-D RT
8
CT simulation 9
AP/PA 8
IMRT 2
SBRT 2
Proton therapy to the
bone metastasis
2
Rating Scale: 1,2,3 usually not appropriate; 4,5,6 may be
appropriate; 7,8,9 usually appropriate.
AP/PA, anteroposterior/posteroanterior; CRT, conformal radiation
therapy; CT, computed tomography; EBRT, external beam radia-
tion therapy; IMRT, intensity-modulated radiation therapy; SBRT,
stereotactic body radiation therapy.
14 KIM ET AL.
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The use of radiopharmaceuticals does not preclude the de-
livery of palliative EBRT. If this patient were to receive fo-
cused EBRT to painful lesions, it would be prudent to consider
the volume of bonemarrowwithin the treatment field given the
potential for diffuse bone marrow suppression that has previ-
ously been reported with radiopharmaceuticals29 (Table 4).
Variant 5 Discussion
This patient has severe pain from a single site of bone me-
tastases with a functional performance status. This patient (as
with all patients) should receive appropriate analgesic therapy
as first-line treatment to provide rapid symptom relief. Sys-
temic therapy for melanoma is an evolving field, but overall
prognosis remains poor. Melanoma is traditionally considered
less sensitive to conventionally fractionated radiotherapy.30,31
The majority of studies evaluating radiotherapy for skeletal
metastases consist of prostate, breast, and lung cancer pa-
tients.20 There are inadequate data available to determine
whether tumor histologies traditionally thought of as ‘‘radio-
resistant’’ respond equally well to palliative radiotherapy as
other more traditionally ‘‘radiosensitive’’ histologies. The
ability of melanoma cell lines to repair sublethal DNA damage
suggests melanoma may be more sensitive to large doses per
fraction or a hypofractionated course of therapy.
Skin and soft-tissue sparing techniques should be utilized.
A single treatment would minimize the patient’s time com-
mitment, transportation requirements, and discomfort from
being transferred on and off the treatment table.32 Fluoro-
scopic simulation, CT simulation, and clinical simulation are
all acceptable methods for planning radiation fields. Treat-
ment with large fractions might be more likely to cause a
temporary pain flare, but anti-inflammatory medications are
capable of minimizing this effect.33 There are no data to
suggest that highly conformal therapy with IMRT, SBRT,
brachytherapy, or proton therapy would improve the outcome
for this patient (Table 5).
Summary
 EBRT successfully provides rapid palliative relief from
painful bone metastases in most cases.
 The acute side effects of palliative EBRT are usually
minimal and self-limiting, whereas long-term side ef-
fects are uncommon and may not be clinically relevant
in a patient group with limited life expectancy.
 Radiotherapy is not commonly recommended for
asymptomatic bone metastases that are not associated
with a risk of pathological fracture as the primary goals
of therapy are pain relief and functional preservation.
 Prospective randomized trials have proven equivalent
pain relief with varied fractionation schemes, including
8 Gy in 1 fraction, 20 Gy in 5 fractions, 24 Gy in 6
fractions, or 30 Gy in 10 fractions. Prolonged courses
Table 4. Clinical Condition: Non-Spine Bone Metastases, Variant 4
66-year-old man with metastatic hormone-refractory prostate cancer. He has widespread osteoblastic skeletal disease with
increasingly painful lesions in the lumbar spine, hips, and extremities. Prior therapy has included hormonal therapy, bi-
sphosphonates, docetaxel chemotherapy, and EBRT to one of his painful hip lesions.
Treatment Rating Comments
Radiopharmaceuticals and EBRT to symptomatic
lesions
8
Radiopharmaceuticals 8
EBRT to most symptomatic lesions 7 EBRT is an effective modality for pain relief of selected
lesions, but the amount of bone marrow treated should
be minimized to prevent compromising the patient’s
remaining systemic therapy options.
Direct hospice placement 5
Changes to systemic therapy only 4
Medical pain management only 4
Radiation therapy dose (if EBRT used)
8 Gy/1 fraction 8
20 Gy/5 fractions 7
24 Gy/6 fractions 7
30 Gy/10 fractions 7
35 Gy/14 fractions 4
40 Gy/20 fractions 3
Treatment technique (if EBRT used)
Clinical simulation 5
Fluoroscopic simulation or 2-D RT 7
CT simulation 8
3-D CRT 8
IMRT 2
SBRT 2
Proton therapy to the bone metastasis 2
Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate.
CRT, conformal radiation therapy; CT, computed tomography; EBRT, external beam radiation therapy; IMRT, intensity-modulated
radiation therapy; SBRT, stereotactic body radiation therapy.
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are associated with a lower incidence of retreatment,
although shorter courses maximize patient and care-
giver convenience by reducing the number of trips to
the radiation department.
 Patients who undergo surgical stabilization for im-
pending or completed pathological fracture of a long
bone may be treated with postoperative radiotherapy to
30 Gy in 10 fractions, 24 Gy in 6 fractions, 20 Gy in 5
fractions, or 8 Gy in a single fraction.
 Reirradiation with EBRT may be feasible and effec-
tive, although retreatment to sites including radiation-
sensitive critical structures should include careful
consideration of the cumulative radiation doses that
may exceed normal tissue tolerance. Reirradiation with
a single 8 Gy fraction is not inferior to multiple-fraction
radiation and has less acute toxicity.
 Management of metastatic bone disease is palliative. A
multidisciplinary team of care providers, including the
palliative care team, should be available to the patient.
Goals of care should be defined with the patient. Hos-
pice referral should be considered if the life expectancy
is 6 months or less, but this does not preclude the use of
radiation for pain control.
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